Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

18.38
-0.8150-4.25%
Volume:3.86M
Turnover:70.27M
Market Cap:3.43B
PE:-5.49
High:19.00
Open:18.96
Low:17.93
Close:19.19
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.70
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.88
PE(LYR):-5.29

Loading ...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 21

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 21

Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy

Reuters
·
May 20

Dyne Therapeutics Announces Initiation of Phase 3 Forzetto Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd) Ahead of Planned Bla Submission for U.S. Accelerated Approval

THOMSON REUTERS
·
May 20

Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital

TIPRANKS
·
May 16

Dyne Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16

Stock Track | Dyne Therapeutics Plummets 5.03% Intraday After Price Target Cut

Stock Track
·
May 16

Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI

TIPRANKS
·
May 15

Piper Sandler Remains a Buy on Dyne Therapeutics (DYN)

TIPRANKS
·
May 14

Dyne Therapeutics Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

Dyne Therapeutics to join RBC Capital Markets healthcare conference fireside chat

Reuters
·
May 13

Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

Dyne Therapeutics price target raised to $24 from $23 at Bernstein

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Dyne Therapeutics (DYN)

TIPRANKS
·
May 13

Dyne Can Unlock Value in Two Drug Prospects, RBC Says

MT Newswires Live
·
May 13

Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)

TIPRANKS
·
May 12

Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate

Benzinga Earnings
·
May 11

Dyne Therapeutics Q1 adjusted EPS beats expectations on lower expenses

Reuters
·
May 11

Earnings Flash (DYN) Dyne Therapeutics Posts Q1 Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss

MT Newswires Live
·
May 11

Dyne Therapeutics Q1 Operating Expenses USD 125.276 Million

THOMSON REUTERS
·
May 11